Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.

Persson, Frederik; Nyström, Thomas; Jørgensen, Marit E; Carstensen, Bendix; Gulseth, Hanne L; Thuresson, Marcus; Fenici, Peter; Nathanson, David; Eriksson, Jan W; Norhammar, Anna; Bodegard, Johan; Birkeland, Kåre I

Persson, Frederik; Nyström, Thomas; Jørgensen, Marit E; Carstensen, Bendix; Gulseth, Hanne L; Thuresson, Marcus; Fenici, Peter; Nathanson, David; Eriksson, Jan W; Norhammar, Anna; Bodegard, Johan; Birkeland, Kåre I.

Affiliation

Persson F; Steno Diabetes Centre, Copenhagen, Denmark.
Nyström T; Karolinska Institutet, Södersjukhuset, Stockholm, Sweden.
Jørgensen ME; Steno Diabetes Centre, Copenhagen, Denmark.
Carstensen B; Steno Diabetes Centre, Copenhagen, Denmark.
Gulseth HL; Oslo University Hospital, Oslo, Norway.
Thuresson M; Statisticon AB, Uppsala, Sweden.
Fenici P; AstraZeneca, Cambridge, UK.
Nathanson D; Karolinska Institutet, Södersjukhuset, Stockholm, Sweden.
Eriksson JW; Uppsala University, Uppsala, Sweden.
Norhammar A; Karolinska Institutet, Stockholm, Sweden.
Bodegard J; Capio S:t Görans Hospital, Stockholm, Sweden.
Birkeland KI; AstraZeneca Nordic-Baltic, Oslo, Norway.

Diabetes Obes Metab ; 20(2): 344-351, 2018 02.

Article in En | MEDLINE | ID: mdl-28771923

Subject(s)

Benzhydryl Compounds/therapeutic use; Cardiovascular Diseases/prevention & control; Diabetes Mellitus, Type 2/drug therapy; Diabetic Angiopathies/prevention & control; Diabetic Cardiomyopathies/prevention & control; Glucosides/therapeutic use; Membrane Transport Modulators/therapeutic use; Aged; Benzhydryl Compounds/adverse effects; Cardiovascular Diseases/complications; Cardiovascular Diseases/epidemiology; Cardiovascular Diseases/ethnology; Denmark/epidemiology; Diabetes Mellitus, Type 2/complications; Diabetes Mellitus, Type 2/ethnology; Diabetes Mellitus, Type 2/metabolism; Diabetic Angiopathies/epidemiology; Diabetic Angiopathies/ethnology; Diabetic Cardiomyopathies/epidemiology; Diabetic Cardiomyopathies/ethnology; Dipeptidyl-Peptidase IV Inhibitors/adverse effects; Dipeptidyl-Peptidase IV Inhibitors/therapeutic use; Female; Follow-Up Studies; Glucosides/adverse effects; Humans; Hyperglycemia/prevention & control; Hypoglycemia/chemically induced; Hypoglycemia/prevention & control; Incidence; Kaplan-Meier Estimate; Male; Membrane Transport Modulators/adverse effects; Middle Aged; Norway/epidemiology; Proportional Hazards Models; Risk; Sodium-Glucose Transporter 2/metabolism; Sweden/epidemiology

Key words

DPP-4 inhibitor; cardiovascular disease; dapagliflozin; diabetes complications; hypoglycaemia; type 2 diabetes

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Benzhydryl Compounds / Cardiovascular Diseases / Diabetes Mellitus, Type 2 / Diabetic Angiopathies / Membrane Transport Modulators / Diabetic Cardiomyopathies / Glucosides Type of study: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Country/Region as subject: Europa Language: En Journal: Diabetes Obes Metab Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2018 Type: Article Affiliation country: Denmark

Fulltext

XML

PubMed Links

Search on Google